Rigel (RIGL) EVP Furey reports 3,968-share disposition, holding 35,862

Rhea-AI Filing Summary

Rigel Pharmaceuticals executive Raymond J. Furey, EVP, GC, CCO & Corp Sec, reported a disposition of common stock. On February 2, 2026, he disposed of 3,968 shares of Rigel common stock at $36.01 per share, reported with transaction code F.

After this transaction, Furey directly beneficially owned 35,862 common shares, which the disclosure notes includes 1,000 shares acquired under Rigel’s stock purchase plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Furey Raymond J.

(Last) (First) (Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, GC, CCO & Corp Sec

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		F		3,968	D	$36.01	35,862(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 1,000 shares acquired under the Issuer's stock purchase plan.

	/s/ Raymond Furey	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Rigel Pharmaceuticals (RIGL) report for Raymond J. Furey?

Rigel Pharmaceuticals reported that executive Raymond J. Furey disposed of 3,968 shares of common stock. The transaction occurred on February 2, 2026, was coded as an F transaction, and was executed at a price of $36.01 per share.

How many Rigel Pharmaceuticals (RIGL) shares does Raymond J. Furey own after this Form 4?

After the reported transaction, Raymond J. Furey beneficially owns 35,862 shares of Rigel common stock. The filing specifies that this total includes 1,000 shares acquired under Rigel’s stock purchase plan, and the ownership is reported as direct.

What was the price per share in Raymond J. Furey’s February 2, 2026 Rigel (RIGL) transaction?

The reported disposition by Raymond J. Furey was executed at $36.01 per share. The Form 4 shows 3,968 shares of Rigel Pharmaceuticals common stock disposed of at this price, using transaction code F, on February 2, 2026.

What does transaction code F indicate in the Rigel (RIGL) Form 4 for Raymond J. Furey?

The Form 4 lists the transaction involving 3,968 shares of Rigel common stock under transaction code F. This code is presented in the official table, identifying the nature of the disposition as categorized by Section 16 reporting rules.

Does Raymond J. Furey’s Rigel (RIGL) holding include shares from a stock purchase plan?

Yes. A footnote explains that Furey’s beneficial ownership includes 1,000 shares acquired under Rigel’s stock purchase plan. These shares are part of his total 35,862 directly held Rigel common shares following the reported transaction.

What position does Raymond J. Furey hold at Rigel Pharmaceuticals (RIGL) in this Form 4?

The Form 4 identifies Raymond J. Furey as an officer of Rigel Pharmaceuticals. His full title is EVP, GC, CCO & Corp Sec, indicating senior executive roles in legal, compliance, and corporate secretary functions at the company.